Diamond Equity Comments on MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Equities research analysts at Diamond Equity issued their Q1 2026 earnings per share (EPS) estimates for MAIA Biotechnology in a note issued to investors on Tuesday, March 25th. Diamond Equity analyst H. Diamond anticipates that the company will earn ($0.18) per share for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.30) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.69) EPS.

MAIA Biotechnology Price Performance

MAIA stock opened at $1.63 on Wednesday. The company’s 50 day moving average price is $1.85. MAIA Biotechnology has a 52-week low of $1.46 and a 52-week high of $5.99. The firm has a market capitalization of $42.64 million, a price-to-earnings ratio of -1.18 and a beta of 0.20.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its holdings in shares of MAIA Biotechnology by 22.9% during the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after buying an additional 35,821 shares during the period. XTX Topco Ltd acquired a new position in MAIA Biotechnology during the 3rd quarter worth $31,000. Finally, Jane Street Group LLC acquired a new position in MAIA Biotechnology during the 4th quarter worth $77,000. Institutional investors and hedge funds own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.